Acedapsone is the INN for diacetyl
dapsone. It was synthesized and developed in 1937 by
Ernest Fourneau and his team in the pharmaceutical chemistry laboratory of
Pasteur Institute,[1] and it was marketed as Rodilone by the
Rhône-Poulenc company.[2]
It is a long-acting
prodrug of dapsone. It is used for treating
leprosy.[3]
It crystallises as pale yellow needles from
diethyl ether, and as leaflets from dilute
ethanol. It is slightly soluble in water.[citation needed]
Acedapsone is conveniently prepared by acetylation of dapsone.
References
^Fourneau E,
Tréfouël J, Nitti F,
Bovet D (July 1937). "Chimiothérapie de l'infection pneumococcique par la di-(p-acétylaminophényl)-sulfone (1399 F)". Compt. Rend. Acad. Sci. (in French). 205: 299.
^Fourneau JP (1987). "Ernest Fourneau, fondateur de la chimie thérapeutique française: feuillets d'album". Revue d'Histoire de la Pharmacie. (in French). 75 (275): 335–55.
doi:
10.3406/pharm.1987.2904.
^Elslager EF, Gavrilis ZB, Phillips AA, Worth DF (May 1969). "Repository drugs. IV. 4',4'''-Sulfonylbisacetanilide (Acedapsone, DADDS) and related sulfanilylanilides with prolonged antimalarial and antileprotic action". Journal of Medicinal Chemistry. 12 (3): 357–63.
doi:
10.1021/jm00303a003.
PMID4892242.
^Raiziss GW, Clemence LW, Severac M, Moetsch JC (1939). "Chemistry and Chemotherapy of 4,4′-Diaminodiphenylsulfone, 4-Amino-4′-hydroxy-diphenylsulfone and Related Compounds". Journal of the American Chemical Society. 61 (10): 2763–2765.
doi:
10.1021/ja01265a060.